This is a technical overview of an INVAMED device within the oncology ablation portfolio. Because ablation is a local therapy, tumor size, number, location relative to vessels and organs, and overall clinical status all influence whether it is appropriate, as determined by a multidisciplinary clinician team. As a medical device manufacturer, INVAMED develops technologies in this area; the information here is educational and not medical advice.
Background: Percutaneous Tumor Ablation
Beyond needle-based approaches, focused laser energy delivered through endoscopic instruments can be used trans-urethrally to vaporize or coagulate bladder tumors and to treat benign prostatic hyperplasia (BPH) with the aim of limiting bleeding. Because ablation is a local therapy, tumor size, number, location relative to vessels and organs, and overall clinical status all influence whether it is appropriate, as determined by a multidisciplinary clinician team. Percutaneous tumor ablation is a group of minimally invasive techniques in which energy is delivered through a needle-like applicator, placed through the skin under imaging guidance, to destroy a focal tumor in situ.
HyperTiss Intracavitary Hypothermia Set for Bladder Cancer Treatment: Overview
Intracavitary hypothermia set for bladder cancer treatment: controlled hypothermia delivery directly to the bladder for enhanced chemotherapy efficacy; authorized for the European market oncology device (official meta description). Matches the category-page FAQ describing combined temperature therapy and intravesical chemotherapy to improve drug penetration into tumor tissue.
Technical Specifications
Specifications per INVAMED product documentation; confirm current details in the official IFU.
| Attribute | Detail |
|---|---|
| Specification | Intracavitary (intravesical) temperature-therapy set |
| Specification | Used adjunctively with intravesical chemotherapy for bladder cancer |
How It Works and Where It Fits
INVAMED groups its ablation portfolio by the energy modality and anatomical target, offering radiofrequency platforms for soft tissue and bone as well as an intracavitary hypothermia set. Each device is intended for use by trained clinicians under appropriate image guidance and per the instructions for use (IFU). Cryoablation destroys tissue by cycles of freezing and thawing, forming an ice ball whose margin can often be visualized on cross-sectional imaging during the procedure. Microwave ablation generates an oscillating electromagnetic field at the antenna tip that agitates water molecules, producing frictional heat that can create a cytotoxic ablation zone in seconds to minutes.
Key Considerations
- Image guidance with ultrasound, CT, or other modalities supports accurate applicator placement and monitoring of the treatment zone.
- Manufacturer descriptions of INVAMED platforms reflect intended design and applications rather than guaranteed individual outcomes.
- For lesions near large vessels, the heat-sink effect can influence the completeness of heat-based ablation and is factored into planning.
Frequently Asked Questions
Does ablation replace surgery?
Not necessarily; ablation is a local, minimally invasive option that may be considered instead of or alongside surgery in appropriately selected patients, and the decision is made within a multidisciplinary team.
Is the HyperTiss set an ablation device?
INVAMED describes HyperTiss as an intracavitary (intravesical) temperature-therapy set intended for adjunctive use with intravesical chemotherapy in bladder cancer, rather than as a standalone tumor ablation device.
What radiofrequency ablation systems does INVAMED offer?
INVAMED offers the Peta RFA System, positioned for soft-tissue, liver, and nerve applications, the multi-application ThermoEdge RFA Platform, and the Fusion Intraosseous RFA System for spinal tumors.
About INVAMED
Device availability and regulatory status vary by country. Please contact INVAMED or your authorized local distributor for current regulatory information applicable to your region.
Clinical and Technical Context
INVAMED's ablation focus is centered on its radiofrequency platforms and intracavitary hypothermia set, so modality selection is made by the treating team based on available tools and indications. Achieving an adequate ablation margin around the tumor is a recognized goal in the literature, and the treating clinician judges whether a single or overlapping-ablation approach is warranted. INVAMED's Peta Radiofrequency Ablation (RFA) System is a generator-based ablation platform offered in variants for soft-tissue and liver tumor ablation as well as nerve (pain) ablation, and the multi-application ThermoEdge RFA Platform is positioned for liver and kidney tissue resection, cysts, and endometrial ablation. Image guidance, applicator trajectory, and the decision to treat percutaneously versus by another route remain clinical judgments made by the operator.
Related on INVAMED
- Oncology Ablation — product category
- A Clinical Introduction to Laser Trans-Urethral Ablation
- Microwave Ablation (MWA) Systems Explained — A Technical Guide
- Understanding Radiofrequency Ablation (RFA) for Liver Tumors
Important Disclaimer
This content is educational and technical in nature and must not be interpreted as medical advice or as a promise of any clinical outcome. Individual results depend on many factors and can only be evaluated by a treating physician. Figures attributed to INVAMED reflect manufacturer or published data and are not a guarantee of results. All INVAMED devices are to be used by trained clinicians per the approved IFU, and availability is subject to local regulatory status.
Reviewed by the INVAMED Medical Affairs team. Content is educational and technical in nature.